BioCentury | Sep 16, 2013
Company News

Clavis, Aqualis Offshore deal

...acquire engineering and marine consultancy firm Aqualis in a NOK70 million ($11.5 million) stock deal. Clavis...
...share purchase agreement and shareholder approval at an October meeting. Carnegie A/S is Clavis' advisor. Clavis...
...designation in the EU to treat AML (see BioCentury, April 8 & May 20). Clavis Pharma ASA (OSE:CLAVIS...
BioCentury | Sep 9, 2013
Financial News

Clavis proposes rights offering of units

...Clavis Pharma ASA (OSE: CLAVIS), Oslo, Norway Business: Drug delivery, Cancer, Infectious Date announced: 9/4/13 Type...
BioCentury | Jul 11, 2013
Distillery Therapeutics

Indication: Cancer

...is in Phase I/II testing to treat non-small cell lung cancer (NSCLC) and prostate cancer. Clavis Pharma ASA...
BioCentury | Jul 1, 2013
Finance

2Q Stock Wrap-Up: If it ain't broke

...compound is in Phase II for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) Clavis Pharma ASA (OSE:CLAVIS...
...reports of life-threatening or fatal hypersensitivity reactions. 5/14/13 Clavis Pharma ASA (OSE:CLAVIS) ND $29.0 0.57 3/31/13 $12.8 Clavis...
BioCentury | Jun 10, 2013
Finance

Finding a 4-leaf clover

...a Phase II trial in metastatic pancreatic cancer. The program, which Clovis in-licensed from Clavis Pharma ASA (OSE:CLAVIS...
BioCentury | May 27, 2013
Company News

Clavis management update

...Clavis Pharma ASA (OSE:CLAVIS), Oslo, Norway Business: Drug delivery, Cancer, Infectious Transitioned: Gunnar Manum to acting...
BioCentury | May 27, 2013
Finance

Demand disequilibrium

...decline is due to a combination of cost cutting, fundraisings and clinical setbacks. For instance, Clavis Pharma ASA...
...Group plc (LSE:AKT), London, U.K. Bio-Gal Ltd. , Gibraltar, U.K. Diaxonhit (Euronext:ALEHT), Paris, France Clavis Pharma ASA (OSE:CLAVIS...
BioCentury | May 27, 2013
Company News

Clavis board of directors update

...Clavis Pharma ASA (OSE:CLAVIS), Oslo, Norway Business: Drug delivery, Cancer, Infectious Transitioned: Martin Nes, a director...
BioCentury | May 20, 2013
Company News

Clavis cancer news

...NOK75.1 million ($12.8 million). Clavis had a 2012 operating loss of NOK104 million ($18.7 million). Clavis...
...Last November, Clavis and former partner Clovis Oncology Inc. (NASDAQ:CLVS, Boulder, Colo.) discontinued development of Clavis'...
...cancer compound CP-4200 , an LVT derivative of azacitidine (see BioCentury, Nov. 19, 2012). Clavis Pharma ASA (OSE:CLAVIS...
BioCentury | Apr 8, 2013
Finance

Highlights of weekly biotech stock moves

...to submit an MAA in Europe by the end of the month. Clinical milestones Clavis Pharma ASA (OSE:CLAVIS...
...therapy in a Phase III trial to treat late-stage acute myelogenous leukemia (AML) (see B14). Clavis...
...remaining assets are in preclinical testing, including cancer compound CP-4200 . At Dec. 31, 2012, Clavis...
Items per page:
1 - 10 of 130
BioCentury | Sep 16, 2013
Company News

Clavis, Aqualis Offshore deal

...acquire engineering and marine consultancy firm Aqualis in a NOK70 million ($11.5 million) stock deal. Clavis...
...share purchase agreement and shareholder approval at an October meeting. Carnegie A/S is Clavis' advisor. Clavis...
...designation in the EU to treat AML (see BioCentury, April 8 & May 20). Clavis Pharma ASA (OSE:CLAVIS...
BioCentury | Sep 9, 2013
Financial News

Clavis proposes rights offering of units

...Clavis Pharma ASA (OSE: CLAVIS), Oslo, Norway Business: Drug delivery, Cancer, Infectious Date announced: 9/4/13 Type...
BioCentury | Jul 11, 2013
Distillery Therapeutics

Indication: Cancer

...is in Phase I/II testing to treat non-small cell lung cancer (NSCLC) and prostate cancer. Clavis Pharma ASA...
BioCentury | Jul 1, 2013
Finance

2Q Stock Wrap-Up: If it ain't broke

...compound is in Phase II for acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS) Clavis Pharma ASA (OSE:CLAVIS...
...reports of life-threatening or fatal hypersensitivity reactions. 5/14/13 Clavis Pharma ASA (OSE:CLAVIS) ND $29.0 0.57 3/31/13 $12.8 Clavis...
BioCentury | Jun 10, 2013
Finance

Finding a 4-leaf clover

...a Phase II trial in metastatic pancreatic cancer. The program, which Clovis in-licensed from Clavis Pharma ASA (OSE:CLAVIS...
BioCentury | May 27, 2013
Company News

Clavis management update

...Clavis Pharma ASA (OSE:CLAVIS), Oslo, Norway Business: Drug delivery, Cancer, Infectious Transitioned: Gunnar Manum to acting...
BioCentury | May 27, 2013
Finance

Demand disequilibrium

...decline is due to a combination of cost cutting, fundraisings and clinical setbacks. For instance, Clavis Pharma ASA...
...Group plc (LSE:AKT), London, U.K. Bio-Gal Ltd. , Gibraltar, U.K. Diaxonhit (Euronext:ALEHT), Paris, France Clavis Pharma ASA (OSE:CLAVIS...
BioCentury | May 27, 2013
Company News

Clavis board of directors update

...Clavis Pharma ASA (OSE:CLAVIS), Oslo, Norway Business: Drug delivery, Cancer, Infectious Transitioned: Martin Nes, a director...
BioCentury | May 20, 2013
Company News

Clavis cancer news

...NOK75.1 million ($12.8 million). Clavis had a 2012 operating loss of NOK104 million ($18.7 million). Clavis...
...Last November, Clavis and former partner Clovis Oncology Inc. (NASDAQ:CLVS, Boulder, Colo.) discontinued development of Clavis'...
...cancer compound CP-4200 , an LVT derivative of azacitidine (see BioCentury, Nov. 19, 2012). Clavis Pharma ASA (OSE:CLAVIS...
BioCentury | Apr 8, 2013
Finance

Highlights of weekly biotech stock moves

...to submit an MAA in Europe by the end of the month. Clinical milestones Clavis Pharma ASA (OSE:CLAVIS...
...therapy in a Phase III trial to treat late-stage acute myelogenous leukemia (AML) (see B14). Clavis...
...remaining assets are in preclinical testing, including cancer compound CP-4200 . At Dec. 31, 2012, Clavis...
Items per page:
1 - 10 of 130